Please assess the completion status of the following clinical trial:

Trial Title: Growth Hormone Treatment in Children With Phelan McDermid Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Known pathogenic deletions or mutations in SHANK3 gene diagnosed by array CGH and/or direct sequencing.~* Children between 2 and 12 years of age.~* Open epiphyses on bone age x ray~Exclusion Criteria:~* closed epiphyses;~* active or suspected neoplasia;~* intracranial hypertension;~* hepatic insufficiency;~* renal insufficiency;~* cardiomegaly/valvulopathy;~* history of allergy to growth hormone or any component of the formulation (mecasermin);~* history of extreme prematurity (\<1000 grams) with associated early neo-natal complications, e.g. intra-cerebral~* hemorrhage, prolonged hypoxia, prolonged hypoglycemia;~* patients with comorbid conditions who are deemed too medically compromised to tolerate the risk of experimental treatment with growth hormone.~* Patient with visual problems that preclude the use of VEP's

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Phelan-McDermid syndrome (Type: EXPERIMENTAL): Patients with Phelan-McDermid syndrome receive 12 weeks of growth hormone therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).